SR-17018: A Novel Biased Opioid Like Compound and Its Promise for Safer Pain Relief
Background and Discovery
SR-17018 was first described in the scientific literature by Laura Bohn and colleagues in 2017. Wikipedia Scientists at Scripps Research in Florida developed the compound as part of a broader effort to create pain-relieving substances that activate opioid receptors without inducing many of the dangerous side effects that have driven opioid-related overdoses and deaths. Scripps Research
The compound emerged from a pressing question in pharmacology: is it possible to create a pain medication that works without causing addiction or fatal overdose? Brooks Healing Center SR-17018 represents one of the most promising experimental answers to that question to date.
What Is SR-17018?
SR-17018 is a synthetic research compound that acts on the mu opioid receptor — the same receptor targeted by morphine, oxycodone, heroin, and fentanyl. It is not a street drug and not an approved medication. It is an experimental compound studied in laboratory settings to better understand how opioids affect the brain and body. Brooks Healing Center
Chemically, SR-17018 carries the CAS number 2134602-45-0 and is also known by the synonym 5,6-Dichloro Desmethylchlorphine. Cayman Chemical It was initially developed by The Scripps Research Institute Patsnap Synapse and has since become a key subject of study in opioid pharmacology research.
How It Works: Biased Agonism
The central concept behind SR-17018 is biased agonism — the selective activation of one signaling pathway over another at the same receptor.
When a conventional opioid activates the mu receptor, two major signaling pathways are triggered: G protein signaling, which is associated with pain relief, and beta-arrestin signaling, which is associated with respiratory depression, tolerance, and other side effects. SR-17018 was developed to preferentially activate the G protein pathway while limiting beta-arrestin activation. Brooks Healing Center
More specifically, SR-17018 acts as a biased partial agonist of the μ-opioid receptor (MOR), with strong selectivity for activation of G protein signaling over β-arrestin2 recruitment. Its affinities for the human opioid receptors have been reported to be 11 nM for the MOR, 68 nM for the κ-opioid receptor (KOR), and greater than 10,000 nM for the δ-opioid receptor (DOR). Wikipedia
What makes SR-17018’s mechanism especially distinctive is how it achieves this bias. SR-17018 has been found to act as a non-competitive MOR agonist with nearly irreversible binding to the receptor, resulting in persistent G protein signaling. However, MOR antagonists like naloxone can still fully reverse MOR stimulation by SR-17018, and hence SR-17018 is not an insurmountable MOR agonist. Wikipedia
Additionally, SR-17018 achieves bias against β-arrestin2 recruitment through interactions with μ receptors outside the orthosteric agonist site Patsnap Synapse — meaning it binds differently from where typical opioids attach.
Preclinical Findings: Pain Relief and Respiratory Safety
Analgesia
SR-17018 produces potent and strong analgesic effects in rodents similarly to other MOR agonists like morphine and fentanyl. Wikipedia In mouse models, it has proven particularly effective in neuropathic pain scenarios. In neuropathy pain, the compound was found to be far superior to morphine and oxycodone, and SR-17018 does not decrease breathing. Scripps Research
Respiratory Depression
One of the most significant findings is the dramatically improved respiratory safety profile. It was estimated that the mouse therapeutic window — the quotient of respiratory depression and analgesia — was 26 to 105 for SR-17018, relative to 5 to 21 for morphine and 2 to 5 for fentanyl. Wikipedia This is a substantial advantage, as respiratory depression is the primary cause of death in opioid overdoses.
However, the picture is not entirely straightforward. Although SR-17018 was reported to produce very little respiratory depression in mice with intraperitoneal administration, a subsequent study using oral administration — which has greater bioavailability — unexpectedly found significant respiratory depression with the drug. Wikipedia This highlights the importance of continued research.
Tolerance
Perhaps one of the most clinically meaningful findings concerns tolerance — the phenomenon where a drug becomes less effective over time, requiring higher and higher doses. SR-17018 showed an ability to provide sustained pain relief over time without the development of tolerance. Scripps Research Whereas morphine caused MOR desensitization in the periaqueductal gray, a key brain area implicated in the analgesic effects of MOR agonists, SR-17018 produced no such desensitization. Wikipedia
Withdrawal and Dependence
Substitution with SR-17018 in morphine-tolerant mice restored morphine potency and efficacy, whereas the onset of opioid withdrawal was prevented. This suggests potential applications not only in pain management but also in treating opioid dependence.
Unique Receptor Interaction Profile
SR-17018 shows a strikingly different MOR phosphorylation profile from other MOR biased, partial, and full agonists. Wikipedia Research has shown that SR-17018-stimulated MOR phosphorylation occurred in a delayed manner similar to that observed with buprenorphine and persisted for hours after agonist washout MDPI — a profile unlike most other opioid compounds studied.
Origins at Scripps Research and Future Directions
The paper’s first author, Edward L. Stahl, notes that SR-17018 is “the first biased agonist of the mu opioid receptor that does not lead to tolerance with chronic use,” calling it “a desirable feature for potential use in the context of chronic, severe pain.” Scripps Research
Researchers are also building on SR-17018 to develop next-generation compounds. Researchers at USF Health have discovered a new way opioid receptors can work, finding that certain experimental compounds can amplify pain relief without intensifying dangerous side effects like suppressed breathing. While these newer molecules are not yet considered drug candidates, they provide valuable guidance for future drug design. Patsnap Synapse
Interestingly, the research could influence drug development beyond opioids, as other receptors — including the serotonin 1A receptor — may also be activated in a reverse direction, making this an important drug target in neuropsychiatric disorders, including depression and psychosis. Patsnap Synapse
Emergence as a Designer Drug — and the Risks
SR-17018 was encountered online as a novel designer drug by 2023, and discussion of it on Reddit dramatically increased in 2024. Although technically a designer opioid, SR-17018 is said to have very different effects from other opioids — for instance, producing minimal euphoria. Wikipedia
Despite this, significant caution is warranted. The drug has not been formally studied in humans, implying an unknown safety profile. Wikipedia Some studies suggest that even biased agonists may still produce tolerance and dependence over time, tempering early optimism in this area. Whether it is morphine, fentanyl, or a research compound, activation of the opioid system can still pose serious risks. Brooks Healing Center
Summary
SR-17018 represents one of the most scientifically intriguing opioid compounds to emerge from the biased agonism research paradigm. Its ability to provide robust analgesia with a dramatically reduced risk of respiratory depression and tolerance — at least in preclinical animal models — marks it as a potentially transformative framework for future pain medications. However, the conflicting findings from different administration routes, the lack of human data, and its emergence in unregulated markets all underscore that SR-17018 remains a research compound, not a safe or approved drug. Its greatest value for now lies in what it teaches scientists about the architecture of opioid receptor signaling — and how that knowledge might one day lead to genuinely safer pain relief.
Want to be notified when Claude responds?Notify